Evidence map›Paper›PMID 39405112›Full record

ArticleJCI insight2024

Type 2 innate immunity promotes the development of pulmonary fibrosis in Hermansky-Pudlak syndrome.

Parand Sorkhdini, Kiran Klubock-Shukla, Selena Sheth, Dongqin Yang, Alina Xiaoyu Yang, Carmelissa Norbrun, Wendy J Introne, Bernadette R Gochuico, Yang Zhou

Abstract read
In one paragraph

Article in JCI insight, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. ICOSMolecular medicine (Cambridge, Mass.) · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Parand SorkhdiniDepartment of Molecular Microbiology and Immunology, Brown University, Providence, Rhode Island, USA.
Kiran Klubock-ShuklaDepartment of Molecular Microbiology and Immunology, Brown University, Providence, Rhode Island, USA.
Selena ShethDepartment of Molecular Microbiology and Immunology, Brown University, Providence, Rhode Island, USA.
Dongqin YangDepartment of Molecular Microbiology and Immunology, Brown University, Providence, Rhode Island, USA.
Alina Xiaoyu YangDepartment of Molecular Microbiology and Immunology, Brown University, Providence, Rhode Island, USA.
Carmelissa NorbrunDepartment of Molecular Microbiology and Immunology, Brown University, Providence, Rhode Island, USA.
Wendy J IntroneMedical Genetics Branch, National Human Genome Research Institute (NHGRI), NIH, Bethesda, Maryland, USA.
Bernadette R GochuicoMedical Genetics Branch, National Human Genome Research Institute (NHGRI), NIH, Bethesda, Maryland, USA.
Yang ZhouDepartment of Molecular Microbiology and Immunology, Brown University, Providence, Rhode Island, USA.

Funding

Tracking and Evaluation CoreU54GM115677 · NIGMS · BROWN UNIVERSITY · PI ROUNDS, SHARON IRENE SMITH · 2016 to 2025
$45.0M
Uncoupling of IL-1 beta and VEGF-A Crosstalk Contributes to Impaired Arteriogenesis Response to Ischemia in Chronic Diabetes MellitusP20GM103652 · NIGMS · OCEAN STATE RESEARCH INSTITUTE, INC. · PI HARRINGTON, ELIZABETH O · 2013 to 2022
$21.3M
Brown Respiratory Research Training ProgramT32HL134625 · NHLBI · BROWN UNIVERSITY · PI Elizabeth O Harrington, Sharon Irene Smith Rounds · 2017 to 2026
$5.1M
Targeting CHI3L and its receptors in Hermansky-Pudlak Syndrome-associated lung diseaseR01HL146498 · NHLBI · BROWN UNIVERSITY · PI ZHOU, YANG · 2020 to 2024
$2.2M
Short-Term Training Program to Increase Diversity in Health-Related ResearchR25HL088992 · NHLBI · BROWN UNIVERSITY · PI ABID, RUHUL, DIAZ, JOSEPH A · 2007 to 2024
$1.9M
Intramural NIH HHSNHLBI NIH HHS R01 HL146498NHLBI NIH HHS R25 HL088992NHLBI NIH HHS T32 HL134625NIGMS NIH HHS P20 GM103652NIGMS NIH HHS U54 GM115677
6 · The paper itself

Abstract

Hermansky-Pudlak syndrome (HPS), particularly types 1 and 4, is characterized by progressive pulmonary fibrosis, a major cause of morbidity and mortality. However, the precise mechanisms driving pulmonary fibrosis in HPS are not fully elucidated. Our previous studies suggested that CHI3L1-driven fibroproliferation may be a notable factor in HPS-associated fibrosis. This study aimed to explore the role of CHI3L1-CRTH2 interaction on type 2 innate lymphoid cells (ILC2s) and explored the potential contribution of ILC2-fibroblast crosstalk in the development of pulmonary fibrosis in HPS. We identified ILC2s in lung tissues from patients with idiopathic pulmonary fibrosis and HPS. Using bleomycin-challenged WT and Hps1-/- mice, we observed that ILC2s were recruited and appeared to contribute to fibrosis development in the Hps1-/- mice, with CRTH2 playing a notable role in ILC2 accumulation. We sorted ILC2s, profiled fibrosis-related genes and mediators, and conducted coculture experiments with primary lung ILC2s and fibroblasts. Our findings suggest that ILC2s may directly stimulate the proliferation and differentiation of primary lung fibroblasts partially through amphiregulin-EGFR-dependent mechanisms. Additionally, specific overexpression of CHI3L1 in the ILC2 population using the IL-7Rcre driver, which was associated with increased fibroproliferation, indicates that ILC2-mediated, CRTH2-dependent mechanisms might contribute to optimal CHI3L1-induced fibroproliferative repair in HPS-associated pulmonary fibrosis.

Indexed as

FibroblastsHermanski-Pudlak SyndromeImmunity, InnateMice, KnockoutPulmonary FibrosisAnimalsBleomycinCell ProliferationChitinase-3-Like Protein 1Disease Models, AnimalFemaleHumansLungLymphocytesMaleMiceBleomycinChitinase-3-Like Protein 1FibrosisGenetic diseasesImmunologyInnate immunityPulmonology

Identifiers

PMID39405112
PMCPMC11601950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.